Sugi Predict

Sugi Predict / Targets / PIK3CD

PIK3CD

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform · O00329 · PIK3CD on Sugi Atlas →

336,349 patent compounds predicted against PIK3CD, 178,611 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3CD by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive PHASE2COMPLETED
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 PHASE2NOT_YET_RECRUITING
Paclitaxel and TAK-228 in Urothelial Carcinoma PHASE2UNKNOWN
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules PHASE1COMPLETED
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours PHASE1COMPLETED
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma PHASE1COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PIK3CD binder may also engage these)

ProteinNameSimilarity
O35904 — 1.000 O35904 →
Q8BTI9 — 0.994 Q8BTI9 →
A0A0G2K344 — 0.993 A0A0G2K344 →
P32871 — 0.992 P32871 →
PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0.992 landscape →
O02697 — 0.991 O02697 →
P42337 — 0.991 P42337 →
P42348 — 0.991 P42348 →
Q5D891 — 0.990 Q5D891 →
Q9Z1L0 — 0.989 Q9Z1L0 →
P70600 — 0.989 P70600 →
P42339 — 0.988 P42339 →
Q6AZN6 — 0.988 Q6AZN6 →
PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0.988 landscape →
Q9JHG7 — 0.988 Q9JHG7 →
PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 0.988 landscape →
Q61586 — 0.988 Q61586 →
PTK2B Protein-tyrosine kinase 2-beta 0.987 landscape →
PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 0.987 landscape →
A0A2R8QPS5 — 0.987 A0A2R8QPS5 →
B0R0W9 — 0.987 B0R0W9 →
O88763 — 0.987 O88763 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.987 landscape →
Q6PF93 — 0.986 Q6PF93 →
ELP1 Elongator complex protein 1 0.986 landscape →
Q60629 — 0.986 Q60629 →
Q24087 — 0.986 Q24087 →
Q5BJS0 — 0.986 Q5BJS0 →
B0BM20 — 0.985 B0BM20 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.985 landscape →